Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

Intraperitoneal cefepime a feasible first-line treatment in CAPD-associated peritonitis

22 Nov 2019

Use of intraperitoneal (IP) cefepime monotherapy proves noninferior to conventional combination therapy in the management of continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis, inducing resolution at day 10, according to the results of an open-label trial.

The study randomized 144 adult peritoneal dialysis (PD) patients with CAPD-associated peritonitis to receive either IP monotherapy of cefepime (1g/d; n=70) or IP combination of cefazolin plus ceftazidime (1g/d; n=74) both given as continuous dosing. Baseline demographic and clinical characteristics were similar between the treatment groups.

Resolution of peritonitis at day 10, the primary endpoint, occurred with greater frequency in the monotherapy than in the combination group (82.6 percent vs 81.1 percent; treatment difference, 1.5 percent, 90 percent confidence interval [CI], –9.1 to 12.1; p=0.04).

There was no significant between-group difference in terms of initial response rate (65.7 percent vs 60.8 percent; treatment difference, 4.9 percent, 95 percent CI, –10.8 to 20.6; p=0.5) and complete cure rate (80.0 percent vs 80.6 percent; treatment difference, –0.6 percent, 95 percent CI, –13.9 to 12.8; p=0.7).

In the monotherapy group, peritonitis relapsed in 4.6 percent of patients and recurred in another 4.6 percent as opposed to 4.2 percent and 5.6 percent of patients in the combination-therapy group, respectively (p=0.9 and p=0.8).

All-cause mortality was slightly higher in the monotherapy group (7.1 percent vs 2.7 percent; treatment difference, 4.4 percent, 95 percent CI, –2.6 to 11.5), although the difference was not statistically significant (p=0.2).

The present data suggest that IP cefepime monotherapy may be a reasonable first-line treatment alternative for patients with CAPD-related peritonitis, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.